On April 1, we successfully completed the acquisition of Sasaeah. This strategic acquisition brings Virbac a leadership position in the farm animal vaccines market in Japan, notably in the cattle segment, and a large portfolio of pharmaceutical products for all the major species.

As in other parts of the world, around 10%¹ of dogs in Asia suffer from atopic dermatitis. Since 2022, our teams have been stepping up their efforts to develop our global DailyDerma program in the region. The goal? To better help Asian veterinarians optimize their dermatology practices and improve the management of skin diseases, especially complex atopic dermatitis. 

●    Revenue up 4.9%, enabling market share gains despite difficulties in 2023

●    2023 operating profitability¹ at an all-time high of 23.2% of revenue
     ○ Up 0.4 points compared to 2022 

●    Strong momentum expected in 2024
     ○  Expected revenue growth of 4% to 6% at constant exchange rates and scope
     ○  Operating profitability¹ expected to rise by 0,5 point